Sun Pharmaceutical Industries Limited announced its financial results for the second quarter ended September 30, 2026 (Q2FY27). Consolidated sales grew 11.8% year-on-year to ₹161,000 million. The company reported a profit before exceptional items and tax of ₹44,282 million, up 6.3%. Net profit for the quarter stood at ₹19,885 million.
Sun Pharma Reports Strong Q2FY27 Financials
Sun Pharmaceutical Industries Limited has reported robust financial results for the second quarter of the fiscal year 2027 (Q2FY27), ending September 30, 2026. The company’s consolidated sales witnessed a significant 11.8% year-on-year growth, reaching ₹161,000 million. This performance highlights strong market traction and successful execution of business strategies.
Key Financial Highlights
The profit before exceptional items and tax increased by 6.3% to ₹44,282 million. The reported net profit after tax for the quarter was ₹19,885 million. Furthermore, the company’s adjusted net profit stood at ₹31,620 million. EBITDA for the quarter was reported at ₹47,439 million, marking a 4.8% increase and maintaining a healthy EBITDA margin of 29.3%.
First Half Performance (H1FY27)
For the first half of FY27 (H1FY27), Sun Pharma reported consolidated sales of ₹312,836 million, an increase of 11.0% compared to the same period last year. EBITDA for H1FY27 was ₹91,616 million, up 3.8%, with an EBITDA margin of 29.1%. The net profit for the first half was ₹48,833 million, while the adjusted net profit stood at ₹62,515 million, showing a 2.2% growth.
Segmental Performance
Global Innovative Medicines
Sales from Global Innovative Medicines grew by 6.9% in Q2FY27 to US$ 356 million, contributing 21.1% to total consolidated sales. For H1FY27, these sales reached US$ 707 million, an increase of 9.8%.
India Formulations
India Formulations sales showed strong growth of 17.3% in Q2FY27, amounting to ₹55,523 million. This segment now accounts for 34.5% of total consolidated sales. For H1FY27, India sales grew 16.6% to ₹110,272 million.
US Formulations
US Formulations experienced a decline of 8.2% in Q2FY27, with sales at US$ 455 million, accounting for 27% of total consolidated sales. The company cited the impact of Lenalidomide erosion but noted a slight increase in ex-Lenalidomide sales for the quarter.
Emerging Markets and Rest of World
Emerging Markets Formulations sales increased by 7.6% to US$ 350 million in Q2FY27, representing 20.7% of consolidated sales. Rest of World (RoW) Formulations recorded sales of US$ 241 million, up 3.1%, making up 14.3% of total consolidated sales.
Active Pharmaceutical Ingredients (API)
External API sales grew by 13.7% in Q2FY27 to ₹4,889 million. For H1FY27, API sales were ₹10,861 million, up 11.9%.
Research and Development
R&D investment for Q2FY27 was 4.8% of sales, amounting to ₹7,784 million. Approximately 32.4% of the total R&D spend was directed towards Innovative Medicines R&D.
Organon Acquisition Update
Integration planning for the Organon acquisition is progressing as planned, with regulatory approvals secured in most regions. The deal is anticipated to close by Q4FY27.
Source: BSE
